Investigational drug · Phase 3
Naporafenib
Also called: LXH254, ERAS-254
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Advanced or Metastatic NRAS-mutant Melanoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "Naporafenib"
First trial start
2020
Oct 30, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Naporafenib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
- Advanced or Metastatic NRAS-mutant Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "Naporafenib" as an intervention, largest first.
Novartis PharmaceuticalsNovartis (NVS)
NCT02974725 · 241 participants · Start Feb 24, 2017 · Primary completion Apr 24, 2024
Drug: LXH254; LTT462 and 2 more · For: Non-Small Cell Lung Cancer; Melanoma
Sites: San Diego, California; San Francisco, California; Boston, Massachusetts · 32 sites in all
- Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway AlterationsTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT02607813 · 142 participants · Start Jan 18, 2016 · Primary completion Feb 18, 2022
Drug: LXH254; PDR001 · For: NSCLC; Ovarian Cancer; Melanoma and 1 more
Sites: Boston, Massachusetts; New York, New York; Houston, Texas · 18 sites in all
- Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04417621 · 134 participants · Start Oct 30, 2020 · Primary completion Feb 2, 2027
Drug: LXH254; LTT462 and 2 more · For: Melanoma
Sites: Los Angeles, California; San Francisco, California; Fort Myers, Florida · 36 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04294160 · 122 participants · Start Jul 22, 2020 · Primary completion Sep 25, 2024
Drug: Dabrafenib; LTT462 and 5 more · For: BRAF V600 Colorectal Cancer
Sites: Los Angeles, California; Boston, Massachusetts; Nashville, Tennessee · 18 sites in all
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03333343 · 105 participants · Start Jan 29, 2018 · Primary completion Jul 12, 2027
Drug: EGF816; trametinib and 4 more · For: EGFR-mutant Non-small Cell Lung Cancer
Sites: Toronto, Canada; Cologne, Germany; Essen, Germany · 11 sites in all
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsActive, not recruiting
Erasca, Inc.Industry
NCT05907304 · 86 participants · Start Aug 17, 2023 · Primary completion Jul 1, 2025
Drug: Naporafenib; Trametinib · For: Advanced or Metastatic Solid Tumors
Sites: San Francisco, California; New Haven, Connecticut; Sarasota, Florida · 29 sites in all
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Pivotal-lookingActive, not recruiting
Erasca, Inc.Industry
NCT06346067 · 78 participants · Start Apr 29, 2024 · Primary completion Apr 2028
Drug: Naporafenib; Dacarbazine and 2 more · For: Advanced or Metastatic NRAS-mutant Melanoma
Sites: Phoenix, Arizona; San Francisco, California; Englewood, Colorado · 59 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Dermatologic Toxicities Associated With Novel Pan-RAS/RAF Inhibitors.
He LJ, Hegazy S, Aung PP, et al. · J Cutan Pathol 2026
- High-resolution measurement of ERK activation state reveals determinants of BRAF regulation and drug sensitivity.
Adebanjo AF, Simon JJ, Banales-Mejia F, et al. · bioRxiv 2026
- The absorption, distribution, metabolism, excretion, and pharmacokinetic properties of the pan-rapidly accelerated fibrosarcoma (RAF) inhibitor naporafenib in healthy subjects: An absolute bioavailability and mass balance study.
Lam JL, Shen Z, Vaz A, et al. · Drug Metab Dispos 2026
- Unexpected remission of Darier disease in a melanoma patient treated with trametinib and naporafenib.
Sboui K, Poulalhon N, Thomas L, et al. · JAAD Case Rep 2026
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.
Zeng PYF, Meens J, Karimi AH, et al. · Cell Rep Med 2026
- Targeting pancreatic cancer with combined inhibition of EGFR and RAF.
Brandstetter J, Goldstein L, Schreiber T, et al. · PLoS One 2026
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.